# A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

> **NCT07691489** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 27 (estimated)

## Conditions studied

- Colorectal Cancer
- Adenocarcinoma of the Colon
- Adenocarcinoma of the Rectum

## Interventions

- **DRUG:** Fam-Trastuzumab Deruxtecan-Nxki

## Key facts

- **NCT ID:** NCT07691489
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691489, "A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*